Inotuzumab Ozogamicin Approved in the US for Adult Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Today the US Food and Drug Administration approved inotuzumab ozogamicin as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). Listen to Dr Elias Jabbour of the MD Anderson Cancer Center provide expert commentary and insights on the clinical trial data leading to the US approval of inotuzumab ozogamicin.


Clinical Opinion Poll

How would you treat 75 y/o male with no significant comorbidity diagnosed with Rai stage III CLL (ECOG PS 1, no del17p or del11q, IgVH-unmutated)?